Share on StockTwits

Humana (NYSE:HUM)‘s stock had its “neutral” rating reaffirmed by investment analysts at Credit Suisse in a note issued to investors on Thursday. They currently have a $123.00 price objective on the stock, up from their previous price objective of $121.00. Credit Suisse’s price objective would indicate a potential upside of 4.55% from the company’s current price.

Shares of Humana (NYSE:HUM) traded down 2.24% during mid-day trading on Thursday, hitting $117.65. The stock had a trading volume of 3,029,090 shares. Humana has a 52-week low of $89.60 and a 52-week high of $134.93. The stock’s 50-day moving average is $127.8 and its 200-day moving average is $114.7. The company has a market cap of $18.210 billion and a P/E ratio of 16.92.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $2.19 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.19. During the same quarter in the previous year, the company posted $2.63 earnings per share. Analysts expect that Humana will post $7.82 EPS for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Deutsche Bank reiterated a “sell” rating on shares of Humana in a research note on Wednesday, July 16th. They now have a $110.00 price target on the stock, up previously from $100.00. Separately, analysts at Leerink Swann raised their price target on shares of Humana from $140.00 to $150.00 in a research note on Friday, July 11th. They now have an “outperform” rating on the stock. Finally, analysts at Sterne Agee initiated coverage on shares of Humana in a research note on Friday, June 27th. They set a “neutral” rating and a $139.00 price target on the stock. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $126.25.

Humana Inc (NYSE:HUM) is a health care company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.